How melanoma is treated in real life

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 664-665

  Dummer, Reinhard ^a   Schadendorf, Dirk ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM2 ACTIVATOR PROTEIN; INTERFERON; KEYHOLE LIMPET HEMOCYANIN; MELANOMA VACCINE; QS 21;

ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; DRUG MEGADOSE; EDITORIAL; HUMAN; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; INTERFERONS; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 44249123518     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.664     Document Type: Editorial

References (14)

1. MacKie RM, Bray C, Vestey J, et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer. 2007;96(11):1772-1777.
2. Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2005;210(1):39-44.
3. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17(2):117-127.
4. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150.
5. Grange F, Vitry F, Granel-Brocard F, et al. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol. 2008;144(5):629-636.
6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648.
7. Eggermont AM, Suciu S, Santinami M, et al. EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma: final results of a randomized phase III trial. J Clin Oncol. 2007;25(18 suppl):8504.
8. Wheatley K, Ives N, Eggermont A, et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol. 2007;25(18 suppl):8526.
9. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670- 1677.
10. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25(18 suppl):8508.
11. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised control trial. Lancet. 2005;366(9492):1189-1196.
12. Dummer R, Garbe C, Thompson JA, et al. Randomized dose escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol. 2006;24(7):1188-1194.
13. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709-718.
14. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective- randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis [published online ahead of print February 14, 2008]. Ann Oncol. doi:10.1093/annonc/mdn001.